Skip to search formSkip to main contentSkip to account menu

JI 101

Known as: Angiogenesis Inhibitor JI-101, JI-101, JI101 cpd 
An orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRb), and the… 
National Institutes of Health

Related topics

Related topics

3 relations
Inhibition of Cell ProliferationReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
SENIOR HIGH SCHOOL STUDENTS’ PERCEPTION OF THE EFFECTS OF SPORTS PARTICIPATION ON ACADEMIC PERFORMANCE IN CENTRAL REGION, GHANA
The study compared the perceptions of Senior High School athletes and non-athletes regarding the effects of sports participation… 
2012
2012
Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.
A highly sensitive, rapid assay method has been developed and validated for the estimation of JI-101 in human plasma and urine… 
2012
2012
A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution…
A general practice in bioanalysis is that, whatever the biological matrix the analyte is being quantified in, the validation is… 
2012
2012
A pharmacodynamic study of JI-101, an orally active inhibitor of VEGF-2, PDGF-β, and EphB4 receptors, in patients with refractory/recurrent ovarian cancer.
e13548 Background: JI-101 is an oral multi-kinase inhibitor, which targets VEGFR-2, PDGF-β, and EphB4. By targeting multiple… 
2011
2011
Abstract 3286: Oral bioavailability, permeability, CYP profiling, identification of major metabolites, tissue distribution and excretion profile of a novel triple kinase inhibitor, JI-101 in rats
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Objectives JI-101 is a novel orally active kinase… 
2011
2011
A drug-drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors.
e15077 Background: The effects of JI-101 on the pharmacokinetics (PK) of everolimus and vice versa were investigated in an open… 
2011
2011
Abstract 3592: Preclinical combination strategies for development of JI-101, a selective inhibitor of Ephrin B4, VEGF R2 and PDGF-Rβ
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: JI-101 is a novel, highly selective and… 
2010
2010
Abstract 17: Preclinical and phase 1 trial results of JI-101, a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFRβ
Introduction JI-101 is a highly selective and potent angiogenesis inhibitor with unique EphB4 activity that distinguishes it from… 
2010
2010
196 PK/PD models using a selective Ephrin B4 inhibitor JI-101 alone and in combination with other targeted agents and chemotherapy: Results of preclinical and ex-vivo studies
2010
2010
400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)